Literature DB >> 1481938

Metabolic and respiratory effects of infused sodium acetate in healthy human subjects.

P Burnier1, L Tappy, E Jéquier, D Schneeberger, R Chioléro.   

Abstract

The metabolic and respiratory effects of intravenous 0.5 M sodium acetate (at a rate of 2.5 mmol/min during 120 min) were studied in nine normal human subjects. O2 consumption (VO2) and CO2 production (VCO2) were measured continuously by open-circuit indirect calorimetry. VO2 increased from 251 +/- 9 to 281 +/- 9 ml/min (P < 0.001), energy expenditure increased from 4.95 +/- 0.17 kJ/min baseline to 5.58 +/- 0.16 kJ/min (P < 0.001), and VCO2 decreased nonsignificantly (211 +/- 7 ml/min vs. 202 +/- 7 ml/min, NS). The extrapulmonary CO2 loss (i.e., bicarbonate generation and excretion) was estimated at 48 +/- 5 ml/min. This observation is consistent with 1 mol of bicarbonate generated from 1 mol of acetate metabolized. Alveolar ventilation decreased from 3.5 +/- 0.2 l/min basal to 3.1 +/- 0.2 l/min (P < 0.001). The minute ventilation (VE) to VO2 ratio decreased from 22.9 +/- 1.3 to 17.6 +/- 0.9 l/l (P < 0.005), arterial PO2 decreased from 93.2 +/- 1.9 to 78.7 +/- 1.6 mmHg (P < 0.0001), arterial PCO2 increased from 39.2 +/- 0.7 to 42.1 +/- 1.1 mmHg (P < 0.0001), pH from 7.40 +/- 0.005 to 7.50 +/- 0.007 (P < 0.005), and arterial bicarbonate concentration from 24.2 +/- 0.7 to 32.9 +/- 1.1 (P < 0.0001). These observations indicate that sodium acetate infusion results in substantial extrapulmonary CO2 loss, which leads to a relative decrease of total and alveolar ventilation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1481938     DOI: 10.1152/ajpregu.1992.263.6.R1271

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  8 in total

1.  Anesthetic management of a pediatric patient on a ketogenic diet.

Authors:  Junko Ichikawa; Keiko Nishiyama; Kyoko Ozaki; Misako Ikeda; Yoshitaka Takii; Makoto Ozaki
Journal:  J Anesth       Date:  2006       Impact factor: 2.078

Review 2.  Crystalloid fluid choice in the critically ill : Current knowledge and critical appraisal.

Authors:  Carmen A Pfortmueller; Barbara Kabon; Joerg C Schefold; Edith Fleischmann
Journal:  Wien Klin Wochenschr       Date:  2018-03-02       Impact factor: 1.704

3.  Swift Acetate Glial Assay (SAGA): an accelerated human ¹³C MRS brain exam for clinical diagnostic use.

Authors:  Napapon Sailasuta; Thao T Tran; Kent C Harris; B D Ross
Journal:  J Magn Reson       Date:  2010-09-22       Impact factor: 2.229

4.  Acetate transport and utilization in the rat brain.

Authors:  Dinesh K Deelchand; Alexander A Shestov; Dee M Koski; Kâmil Uğurbil; Pierre-Gilles Henry
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

5.  Acetate alters expression of genes involved in beige adipogenesis in 3T3-L1 cells and obese KK-Ay mice.

Authors:  Satoko Hanatani; Hiroyuki Motoshima; Yuki Takaki; Shuji Kawasaki; Motoyuki Igata; Takeshi Matsumura; Tatsuya Kondo; Takafumi Senokuchi; Norio Ishii; Junji Kawashima; Daisuke Kukidome; Seiya Shimoda; Takeshi Nishikawa; Eiichi Araki
Journal:  J Clin Biochem Nutr       Date:  2016-09-08       Impact factor: 3.114

6.  Acetate-buffered crystalloid infusate versus infusion of 0.9% saline and hemodynamic stability in patients undergoing renal transplantation : Prospective, randomized, controlled trial.

Authors:  Carmen Pfortmueller; Georg-Christian Funk; Eva Potura; Christian Reiterer; Florian Luf; Barbara Kabon; Wilfred Druml; Edith Fleischmann; Gregor Lindner
Journal:  Wien Klin Wochenschr       Date:  2017-03-02       Impact factor: 1.704

Review 7.  Hepatic Arterial Buffer Response in Liver Radioembolization and Potential Use for Improved Cancer Therapy.

Authors:  Stephan Walrand; Michel Hesse; Philippe d'Abadie; François Jamar
Journal:  Cancers (Basel)       Date:  2021-03-26       Impact factor: 6.639

8.  The effect of oral sodium acetate administration on plasma acetate concentration and acid-base state in horses.

Authors:  Amanda Waller; Michael I Lindinger
Journal:  Acta Vet Scand       Date:  2007-12-20       Impact factor: 1.695

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.